STRUCTURE THERAPEUTICS INC (GPCR) Stock News
NASDAQ:GPCR - Nasdaq - US86366E1064 - ADR - Currency: USD
GPCR Latest News, Press Relases and Analysis
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights
Jim Cramer Applauds Texas Instruments (TXN): “Put Up Terrific Numbers”
We recently published a list of Jim Cramer Put These 16 Stocks Under a Microscope. In this article, we are going to take a look at where Texas Instruments Incorporated’s (NASDAQ:TXN) stands against other stocks that Jim Cramer discussed. On Wednesday, Jim Cramer, the host of Mad Money, took to discussing how President Donald Trump’s […]
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.
Pfizer Setback Spurs Rise in Obesity Developers on M&A Hopes
Shares of several biotechs developing obesity drugs rallied on Monday after Pfizer Inc. halted development of its closely-watched experimental pill, as investors bet that the setback could spur dealmaking by Pfizer.
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race.
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.
Why Structure Therapeutics Stock Was Stumbling This Week
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of...
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment.
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be...
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2...
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...